NervGen Pharma (NGEN) stock

Spinal injury medicines , market cap $153M

Medicines for spinal cord injury

Market cap $153M

$1.42

-0.70%

As of Monday's close · Live for Pro members at the open

Quality Score

-1

Poor

In its industry

#145of 291

Biotech

Checks firing

2of 14

Trending down

From 52-week high

-77.5%

Below the 200-day

NGEN's Quality Score fell 2 points on Mon, Oct 26, to -1. Its volume eased back to normal (3 chart checks stopped).

Follow NGEN's trial news. Pro members can get an alert when NervGen Pharma files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NGEN files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2027“The Company continues to expect completion of enrollment in 2H 2027,”Trial start · SEC filing · Aug 13

Key facts on NGEN

Key facts on NGEN
Holding it back	A loss of CA$44M wider than CA$24M a year earlier
Latest filing	10-Q, Mar 31 Filed its quarterly report (10-Q) for the quarter to Dec 31, 2025

2 more reasons behind NGEN's -1, for Pro members.

NGEN catalysts

Coming up

After its last 3 reports it closed +1.1% on average, higher 2 of 3 times.

1 more coming up, with sizes and sources, for Pro members.Get in free →

What's next for NGEN, and how long its cash lasts

Next step the company has named

2H 2027“The Company continues to expect completion of enrollment in 2H 2027,”Trial start · SEC filing · Aug 13

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: RESTOREPhase 3 · Recruiting · 150 people · main data estimated Jul 2027 · NCT07799532

For Pro members: 1 more milestone and 15 filings.

Cash runway Dec 31, 2025 balance sheet

CAD 22.1M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when NGEN files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

Why NGEN scores -1

PoorTrending down, 2 of 14 chart checks firingWhat the Quality Score means

+2Chart checks 2 of 14 firing right now, one point each
−1Size $153M, micro cap

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Run-up, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on NGEN and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:16 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when NGEN's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on NGEN and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

NGEN has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on NGEN, and all 14 on every stock.Get in free →

NGEN RSI today: 25.9, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1425.9
Below 30.
MACD (12, 26, 9)Below signal
Crossed below its signal line 31 sessions ago.
50-day average$1.91
The price is 25.7% below it.
200-day average$2.93
The price is 51.5% below it.
50/200 crossNo cross
The 50-day has been below the 200-day in every session on file.
ADX 1438.0
25 or more, with +DI below -DI.
Support
No swing low under the price in the last year.
Resistance$1.82
Swing high from Aug 13, 28.2% above the price.
High since listing$6.30
From Jan 8, 343.7% above the price.
Low since listing$1.37
From Oct 26, 3.5% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $1.36 to $1.96.
Volume0.5x
Against its 20-day average, for the time of day.

The deep dive on NGEN

What it does and how it makes money1 findingFor Pro members1 finding on what NGEN does and how it makes money, for Pro members
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades NGEN, for Pro members

2 more findings on NGEN, each with its source, for Pro membersGet in free →

How NGEN ranks in Biotech

NGEN is #145 of 291 by Quality Score.

How NGEN ranks in Biotech
1	HALOHalozyme Therapeutics	9/14	21
2	AMRXAmneal Pharmaceuticals	9/14	20
3	RIGLRigel Pharmaceuticals	9/14	19
	NAMSNewAmsterdam Pharma		Open for its score
	NBIXNeurocrine Biosciences		Open for its score
	NGNENeurogene		Open for its score
	NKTRNektar Therapeutics		Open for its score
145	NGENNervGen Pharma	2/14	-1

When does NGEN report earnings, and what happens after?

Expected to report Mon Nov 23, before the open (in 28 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

+1.1%+2.1%0.0%

Mar 31May 18Aug 13

Reported	When	Gap	Reaction	5 sessions
Aug 13, 2026Before open	Before open	+0.6%	0.0%	-0.6%
May 18, 2026Before open	Before open	+1.0%	+2.1%	-41.6%
Mar 31, 2026Before open	Before open	+1.9%	+1.1%	+6.4%

NGEN closed higher after 2 of its last 3 reports.

About NervGen Pharma

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

9 employeesnervgen.com

NGEN's score card

NervGen Pharma (NGEN): Quality Score -1, Poor, #145 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn NGEN's score around: 6 things
1 more filing explained, a plain line each
Real-⁠time prices, no delay

See NGEN's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Oct 26, 2026: NGEN's Quality Score is -1 (Poor), #145 of 291 in Biotech.

Is NGEN a good stock to buy? What its Quality Score says

NGEN scores -1 today, which Breakaway calls Poor. It is #145 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is NGEN's Quality Score?

NGEN scores -1 today, which Breakaway calls Poor (below zero). That is #145 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NGEN's -1.

When does NGEN report earnings?

Expected to report Mon Nov 23, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. NGEN closed higher after 2 of its last 3 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.